Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Components of Income Taxes

For the years ended December 31, 2025 and 2024, the Company’s provision for income tax consisted of (in thousands):

	Year Ended December 31,
	2025		2024
Current:
Federal	$	(18)	$	52
State	15		38
Foreign	8		—
Total Current	$	5	$	90
Deferred:
Federal	$	—	$	21
State	124		(151)
Foreign	—		—
Total Deferred	$	124	$	(130)
Provision for income taxes	$	129	$	(40)

Schedule of Net Income Tax Payments

Net income tax payments in 2025 were as follows:

	Year Ended December 31,
	2025
Federal	$	—
State	38
Foreign	—
Total net income tax payments	$	38

Schedule of Reconciliation of Statutory Federal Income Tax Rate

The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	Year Ended December 31, 2025
	Rate		Amount
U.S. federal statutory tax rate	21.0	%	$	(96)
State taxes, net of federal income tax effect (a)	(23.3)		106
Tax credits - Research and development credits	40.6		(184)
Changes in valuation allowances	53.8		(245)
Nontaxable or nondeductible items
Stock-based compensation	(47.4)		216
IRC Section 162(m) limitation	(55.0)		251
Other adjustments	(3.8)		17
Changes in unrecognized tax benefits	(14.0)		64
Provision for income taxes	(28.1)	%	$	129

(a) State taxes in Indiana and Minnesota made up the majority (greater than 50%) of the tax effect in this category.

	Year ended December 31,
		2024
Tax at statutory federal rate		21.0	%
State taxes, net of federal benefit		3.6
Stock-based compensation		34.8
IRC section 162(m) limitation		29.0
R&D tax credits		(564.7)
Change in valuation allowance		486.1
Other		(15.1)
Provision for income taxes		(5.3)	%

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):

	Year Ended December 31,
	2025		2024
Deferred tax assets:
Net operating loss carryforwards	$	21,832	$	20,564
Inventory	260		462
Accruals	614		366
Depreciation and amortization	4		9
Research and experimental credits	4,304		3,995
Research and experimental expenditures	4,374		6,412
Stock-based compensation	397		428
Right of use liability	735		1,045
Gross deferred tax assets	32,520		33,281
Valuation allowance	(31,337)		(31,343)
Deferred tax assets	1,183		1,938
Deferred tax liabilities:
Right of use asset	(716)		(1,024)
Other	(322)		(646)
Deferred tax liabilities	(1,038)		(1,670)
Net deferred tax assets	$	145	$	268

Schedule of Net Valuation Allowance

The net valuation allowance decreased by less than $0.1 million in 2025, as reflected below (in thousands).

	Year Ended December 31,
	2025	2024
Valuation Allowance at beginning of year	(31,343)	(27,748)
Current Year Change	6	(3,595)
Valuation Allowance at end of year	(31,337)	(31,343)

Schedule of Changes in the Company's Gross Unrecognized Tax Benefits

A summary of changes in the Company’s gross unrecognized tax benefits for the years ended December 31, 2025 and 2024 was as follows (in thousands):

	Year Ended December 31,
	2025		2024
Unrecognized tax expense, beginning of the year	$	1,389	$	473
Decrease related to prior year tax positions	(126)		—
Increase related to prior year tax positions	—		662
Increase related to current year tax positions	184		254
Unrecognized tax expense, end of year	$	1,447	$	1,389